Global Insulin Market US$ 35 Billion by 2021

Global Insulin Market US$ 35 Billion by 2021

The global insulin market is estimated to reach US$ 35 Billion in 2021, expanding at a CAGR of 4.8% from 2017 to 2021, mainly due to increasing global diabetic population and launch of new highly potent, cost-effective drugs in the pipeline candidates by major pharmaceutical companies.

According to the WHOGlobal report on diabetes“, globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. The global prevalence (age-standardized) of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population. This reflects an increase in associated risk factors such as being overweight or obese. Over the past decade, diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries. The lack of access to affordable insulin remains a key impediment to successful treatment and results in needless complications and premature deaths. Insulin and oral hypoglycaemic agents are reported as generally available in only a minority of low-income countries. Moreover, essential medicines critical to gaining control of diabetes, such as agents to lower blood pressure and lipid levels, are frequently unavailable in low- and middle-income countries. Policy and programme interventions are needed to improve equitable access.

Human Insulin and Insulin Analogs are available for insulin replacement therapy. There are three main groups of insulins: Fast-acting, Intermediate-acting and Long-acting insulin. Fast-acting insulin includes rapid acting insulin analogs – Apidra (Glulisine), Humalog (Lispro), Novolog (Aspart), and regular (R) or short-acting human insulin includes Humulin R, Novolin R (human recombinant). Intermediate-acting insulin includes Neutral Protamine Hagedorn (NPH) human insulin – Humulin N, Novolin N (Isophane) and pre-mixed insulin. Mixed or combination insulins includes shorter acting insulin combined with a longer acting insulin such as Humulin 70/30, Novolin 70/30, Novolog 70/30, Humulin 50/50, and Humalog mix 75/25. Long-acting insulin includes long acting insulin analogs Lantus (Glargine), Levemir (Detemir), Basaglar (Glargine).

Affordability of insulin has become a major issue for patients with diabetes in the United States. Synthetic human insulin, once the mainstay of treatment, is much less expensive but is now prescribed less frequently. The price of insulin, particularly insulin analogues, has increased substantially over the past 2 decades.

The global insulin market report estimates the market size (Revenue US$ million – 2014 to 2021) and composition of this market by source type (human, recombinant), mode of action (short-acting insulin, rapid-acting insulin, long-acting insulin, intermediate-acting insulin, premixed insulin), pipeline analysis [rapid-acting insulin – Afrezza, NN1218 (FIAsp); long-acting insulin – IDegLira (Xultophy), LY2605541(novel basal insulin analog), LY2963016 (long acting basal insulin), MK-1293 (sustained release insulin analog), U-300 (Toujeo)] and forecasts growth trends (CAGR% – 2017 to 2021). The report also covers the major competitors operating in the market and provides a bird’s eye view of the different insulin analogs available in the global market. The global insulin market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global insulin market and included in this report are Eli Lilly and Company, Novo Nordisk, Sanofi, Shanghai Fosun Pharmaceuticals, and Thermalin Diabetes, LLC.

  1. Source Type
    • Human
    • Recombinant
  2. Mode of Action
    • Short-Acting Insulin
    • Rapid-Acting Insulin
    • Long-Acting Insulin
    • Intermediate-Acting Insulin
    • Premixed Insulin
  3. Pipeline Analysis
    • Rapid-Acting Insulin
    • Afrezza
    • NN1218 (FIAsp)
    • Long-Acting Insulin
    • IDegLira (Xultophy)
    • LY2605541(Novel Basal Insulin Analog)
    • LY2963016 (Long Acting Basal Insulin)
    • MK-1293 (Sustained Release Insulin Analog)
    • U-300 (Toujeo)
  4. Company Profiles
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Sanofi
    • Shanghai Fosun Pharmaceuticals
    • Thermalin Diabetes, LLC

To request Table of Contents and Sample Pages of this report visit:


2017-11-10T11:33:10+00:00 Categories: Press Releases|